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Maintaining the ability to walk is one of the significant challenges in people with multiple
sclerosis (MS) for keeping a good quality of life as the disease and the aging process
progresses. Overground robotic (OR) wearable exoskeletons are promising tools for
gait rehabilitation, but currently there is no evidence of their clinical effects on patients
with MS. The present study aims to determine the effects of an OR intervention in
people with MS and moderate to severe walking disabilities and ascertain if benefits
are maintained over a follow-up period of 3 months. This randomized controlled trial
will include 36 participants with MS. Inclusion criteria are: older than 18 years, definitive
diagnosis of MS, 4.5–7 points on the EDSS (Expanded Disability Status Scale), and
needing one or two canes or crutches for walking outdoors. Subjects in the control group
will receive conventional physiotherapy sessions at ADEMBI (Asociación de Esclerosis
Múltiple de Bizkaia) provided to control spasticity, maintain articular range and exercise
balance. Subjects in the intervention group will receive the same physiotherapy but
also participate in a progressive OR gait training program assisted by the EksoTM
exoskeleton. The program consists of twice a week individually supervised sessions
in two setting modalities: PreGait and ProStepPlus. The training parameters (duration,
speed, cadence, length of steps) will be set during the first session and the progression
and intensity of the intervention will be adapted to the tolerance of each participant. The
primary outcome of this study is gait speed. Secondary outcomes will include physical
and cognitive performance tests, clinical, fatigue and quality of life assessments, and
changes in the plasma levels of inflammatory cytokines. The present trial is the first
analyzing the effectiveness of an OR intervention for gait training in patients with MS.
It will help clarify the applicability of robotic technologies to clinical practice, extending
the functionality and quality of life of people with MS to face a successful aging process.
(ACTRN12619000014156; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=
376548).
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INTRODUCTION
Multiple sclerosis (MS) is a patchy, inflammatory, autoimmune,
and demyelination disorder of the central nervous system
characterized by the accumulation of progressive neurological
impairment (1). MS presents with a wide range of neurological
symptoms related to the varying degree and location of axonal
and neuronal damage. The disease can follow a variety of clinical
courses and is unpredictable in terms of prognosis. Reduced
mobility and gait dysfunction are the most noticeable signs of
MS; up to 85% of people with MS report difficulty in walking
(2, 3) after 10 years of disease onset. In addition, over 60% of
people with MS experience some degree of cognitive impairment
(4) that correlates with peripheral changes in pro-inflammatory
cytokines such as interleukin 1β (IL-1β) and tumor necrosis
factor α (5). Fatigue and postural control impairment also
appear ubiquitous over the course of MS (6). Increasing evidence
suggests that impaired mobility and symptoms such as fatigue
are important factors contributing to the observed reduction in
quality of life (7) and, in some cases, increased costs (8) associated
with MS. In fact, from mid-life and on, MS disease progression
can negatively impact employment and participation in everyday
activities (9).
An observational study (10) conducted in Canada reported
a rise in the prevalence of MS from 1984 - 1997 specifically
among people in older age groups. This occurred with minimal
changes in the incidence, possibly indicating that patients with
MS were living longer. The same trend was also observed in
other epidemiological studies conducted in Europe (11–13). As
they age, people with MS are at increased risk for developing
comorbidities (14–16), at a time when they are often experiencing
a progression in their disability (17). Older adults with MS
experience limitations in daily-life activities, report low health-
related quality of life status, and express concerns about the
continuous loss of function and mobility with aging (18–21).
People aging with MS also report lower freedom perception
relative to that of their cohort peers and fear that they may
become a burden on family members (22). In summary, people
living with MS are confronted with the challenge of dealing with
the functional deterioration associated with disease progression
while simultaneously dealing with age-related changes. The
resulting decline in functional capacity frequently occurs at a very
young age, leading to approach it as a premature aging process.
People with MS perceive gait as one of the most valuable
physical functions (23), and consequently regard impaired
walking ability as a major physical problem (24). Accordingly,
it is of utmost importance to preserve MS patient’s capacity
to locomote as long as possible to allow for successful
aging. Rehabilitation strategies for MS gait dysfunction have
experienced significant improvement in recent years and have
incorporated new technologies (25). For example, robot-assisted
gait training (RAGT), which has shown to be feasible in patients
with spinal cord injuries (26) and stroke (27), has also been
Abbreviations: MS, multiple sclerosis; RAGT, robot-assisted gait training; EDSS,
Expanded Disability Status Scale; OR, overground robotic; ADEMBI, Asociación
de Esclerosis Múltiple de Bizkaia.
evaluated in MS (28). RAGT consists on a training modality
in which the patient’s body weight is supported by a harness
while walking on a treadmill with the help of a robotic-
driven gait orthosis (29). Morone et al. (30) have identified the
following characteristics of RAGT devices: i) capable of mobility
with different levels of autonomy, ii) could be classified as
either “exoskeletons” (when the movement of specific joints is
controlled [i.e. hip, knee or ankle joint]) or “end-effect robots”
(the device is at the end of the limb, [i.e. the feet are placed on a
footplate]) and iii) could be classified as static (when the patient
remains in a fixed environment) or dynamic (if the device enables
to change the location). RAGT allows therapists to facilitate the
task-oriented practice of walking (31), which potentially leads to
learning-dependent neuroplasticity (32). RAGT allows intensive
gait training without highly demanding therapists and patients,
particularly when treating patients with severe gait impairments.
However, RAGT does not appear to be superior to intensive
overground walking training in people with MS. In a recently
published randomized controlled study of seventy-two patients
affected by severe disability (EDSS 6-7), the effects of 4 weeks
of RAGT intervention was compared with conventional walking
training in terms of gait speed (33). Both therapies were found
to significantly improve gait speed with respect to baseline
assessment, but the study failed to demonstrate group by time
interactions. Similar improvements were observed for most of
the secondary outcomes: walking, endurance, balance, fatigue,
and quality of life. However, the improvements obtained during
the interventions were lost within a few months of program
cessation. Additional studies evaluating RAGT interventions in
people with MS and severe walking disabilities (28, 34–37) have
yielded similar results. Thus, there is a clear need to understand
how best to create stable adaptations that can support and
improve the long-term mobility of patients with MS.
The overground robotic exoskeleton (OR) is a relatively new
advanced technical device being incorporated into the field of
gait rehabilitation. ORs are wearable powered exoskeletons that
allow individuals to walk on hard and flat surfaces in a real-world
setting. They require a patient’s active participation and provide
greater motor control stimulation and enriched multisensory
information (visual, proprioceptive, tactile, and vestibular) than
the RAGT systems (38). Preliminary findings suggest that OR-
assisted gait training may be more beneficial than conventional
walking training in post-stroke patients (39). A recent study
of forty patients with hemiparesis due to stroke compared the
effectiveness of OR and conventional gait training in the chronic
recovery phase (40). OR gait training resulted in a significant
improvement in gait speed, coordination of muscle activations,
and frontoparietal effective connectivity. Additionally, recent
systematic reviews indicate that OR is a feasible treatment for
patients with spinal cord injury (SCI), allowing safe ambulation
in real-world environments (41, 42). However, the effectiveness
of OR gait training interventions for improving mobility in
people with MS has not yet been studied.
Therefore, this study aims to determine the effects of the
addition of an OR intervention to the conventional rehabilitation
program on gait speed in people with MS and moderate to severe
walking disabilities. As a secondary aim, the study will determine
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the effects of the intervention from a multidimensional
perspective, taking into account physical, cognitive and clinical
parameters, fatigue and health-related quality of life of the
participants. Additionally, as MS is accompanied or mediated
by neuro-inflammation, training interventions may stimulate an
anti-inflammatory response contributing to the positive effects of
exercise in patients with MS (43, 44). Thus, the influence of the
intervention on peripheral inflammatory cytokines will also be
analyzed. Finally, this study aims to ascertain if the effects of the
intervention are maintained over a follow-up period of 3 months.
MATERIALS AND METHODS
Study Design and Participants
This is a prospective parallel-assignment, single-blinded,
randomized controlled study. Participants will be randomly
assigned to one of the following groups: the control group (CG)
or the OR group. The study will take place at the Asociación
de Esclerosis Múltiple de Bizkaia (ADEMBI) between January
2019 and December 2019. The assessments will be conducted
by blinded research staff at baseline (T1) and after 3 months
of training (T2). After a 3-month follow-up period, a final
assessment will be performed at 6 months (T3). The study
has been designed and results will be reported according
to the CONSORT Statement extension for trials of non-
pharmacological interventions and pragmatic intervention trials
(Figure 1 ). This study was approved by the Ethics Committee
of Clinical Research of Euskadi (CEIm) (Code PS2018017)
and by the Ethics Committee for Research with Biological
Agents of the University of the Basque Country (CEIAB)
(Code M30/2018/073).
Inclusion and Exclusion Criteria,
Recruitment, and Randomization
Subjects will be considered eligible for the study if they fulfill all
of the following criteria: (a) aged ≥ 18 years, (b) diagnosis of
MS according to McDonald criteria (45), (c) moderate to severe
gait impairments defined by an Expanded Disability Status Scale
(EDSS) score ranging from 4.5 to 7 (46), and (d) the need for one
or two canes or crutches for walking outdoors.
Participants will be excluded if they (a) have a neurological
pathology in addition to MS, (b) have some musculoskeletal
disorder that could limit the extension of the hip and knee or
the plantar flexion of the ankle, (c) have suffered an outbreak of
MS during the 3 months prior to the start of the study, (d) are
under non-stable pharmacological treatment or with treatments
expected to be modified during the study, or (e) have received
treatment with botulinum toxin in the 12 weeks prior to the
beginning of the study.
Recruitment will be done at ADEMBI. Informative meetings
will be organized to provide detailed oral and written information
about the study, including objectives, studied variables, and
methodology, to both potential participants and their families.
Participants will sign, indicating informed consent, after
fully understanding the study. Using a coin-tossing sequence
generation, participants will be randomly allocated at a 1:1 ratio
to either the control group (CG) or the intervention group (OR).
The assignment will be conveyed via sealed opaque envelopes.
Control Group Intervention (CG)
Subjects in the CG will participate in the routine physiotherapy
sessions provided to all patients with MS at ADEMBI. ADEMBI
is a reference MS center for providing expertise and specialized
rehabilitation to people with MS, where all the participants
receive individualized assistance throughout the year following
the latest recommendations and clinical guidelines for managing
the disease. The duration of each session is one hour; in these
sessions, conventional methods of physiotherapy are provided to
control spasticity, maintain articular range and exercise balance.
Overground Robotic Gait Training Group
(OR)
Subjects in the intervention group will receive the same
physiotherapy treatments scheduled for the control group and
will participate in 3 months of individualized and progressive
gait training assisted by an OR (EksoTM, Ekso Bionics, USA).
EksoTM is a powered, wearable exoskeleton with actuated hips
and knees that provides assistance to lower limb segments during
movement. The gait training program’s technical content is based
on a literature review, author’s expertise, and field experience
(Table 1). It has been designed taking into account the multi-
modal training approach, as has been recommended by expert
physical therapists on the rehabilitation of patients with MS
(47), to allow the “far transfer effect”. This effect refers to the
occurrence of transferring the improved performance from a
specific function to different untrained functional domains (48).
Interventions will be individually supervised by experienced
physiotherapists properly trained in EksoTM driving and will
consist of twice weekly sessions assisted by the wearable
exoskeleton in two modalities: 1) PreGait: to exercise static
balance and weight shifts at the beginning of each session; 2)
ProStepPlus: to gait train, with steps triggered by the user’s lateral
weight shift. Subjects will wear their own shoes and orthotics
during the training sessions. The parameters (duration, speed,
cadence, length of the steps, robotic assistance, etc.) of the
intervention will be adapted to each participant, and the duration
of the training sessions progressively increased as participants
increase their tolerance, aiming to achieve 20-40 minutes of
OR training (including the exoskeleton donning and doffing) by
the end of the 3 month training period. The session will end
with 10 minutes of cryotherapy on knee extensors and ankle
plantar flexors. There will be at least 48 hours between training
sessions, and goals will be adapted in response to illness, injury,
or physical symptoms.
Primary Outcome: Gait Speed
The assessments will be performed at ADEMBI by blinded
research staff at baseline (T1), 3 months (T2), and 6
months (T3). Participants will walk through a 10-meters
corridor at their own habitual speed. The time spent in
performing the test will be measured through photoelectric cells
(Polifemo,Microgate, Italy), and afterwards, gait speed calculated
Participants will be allowed to wear their own footwear, orthoses,
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FIGURE 1 | Flow diagram of the study.
and prescribed usual assistive device (crutches, canes). This
test will be performed as the first assessment to avoid possible
muscle fatigue.
Secondary Outcomes
Secondary outcomes will include physical and cognitive
performance tests (Table 2), and clinical, fatigue and quality of
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TABLE 1 | Technical content of the OR gait training program.
PreGait 2–3 exercises of static weight shift in progressive difficulty to identify:
(a) Symmetric distribution of weight
(b) A given lateral weight displacement point
1st Month 2nd Month 3rd Month
Patients assisted by acoustic stimuli Reduction of external stimuli and lateral weight
displacement point
Lateral weight displacement and step on the site
ProStepPlus Gait training sessions of progressive length and difficulty according to patient tolerance (maximum 40 min/session)
1st Month 2nd Month 3rd Month
Patients assisted by acoustic stimuli when
reaching the lateral point to trigger the step
Reduction of external stimuli and lateral weight
displacement point trigger
Increase the duration and speed of the sessions
targeting a functional gait
EksoTM bilateral full adaptive assistance EksoTM bilateral full adaptive assistance EksoTM bilateral full adaptive assistance
Cryotherapy 10min on knee extensors and ankle plantar flexors in a supine position.
TABLE 2 | Physical and cognitive assessment tests and questionnaires.
Test (references) Functions/Parameters Description
Handgrip strength test (Jamar dynamometer)
(46)
Dominant hand grip strength Squeeze the dynamometer with maximum isometric effort for about 5 s
Timed Up and Go test (47) Dynamic balance Get up from a chair without upper-limb assistance, walk 3m at a normal pace,
turn and sit back in the chair
Short Physical Performance Battery (SPPB) (48) Lower extremity function: static
balance, gait speed, and getting in
and out of a chair
Side-by-side, semi-tandem, and tandem stands (10 s); 4m walk test at
comfortable speed; and 5 quick sit to stands from a chair without upper-limb
assistance
Berg balance test (49) Postural stability Performance of 14 functional tasks
Yale Physical Activity Scale (50) Physical activity Type, amount, pattern, and perceived difficulties of performed physical activities
throughout daily living
Montreal Cognitive Assessment (MoCA) (51) Cognitive dysfunction Covered domains: attention and concentration, executive functions, memory,
language, visuoconstructional skills, conceptual thinking, calculations, orientation









Spasticity Graduation of the resistance encountered
during passively stretching flexor and







21-item scale measuring perceived fatigue
over the last four weeks
EuroQol-5 (54) Health related
quality of life
Covered domains: mobility, self-care,
usual activities, pain/discomfort, and
anxiety/depression
life assessments (Table 3), and the measurement of circulating
inflammatory cytokines.
Participants will self-report their age, gender, marital status,
employment situation, and Barthel index (49). Physical and
cognitive examination will include the following (Table 2): the
handgrip strength test (50) (Jamar dynamometer), TimedUp and
Go test (51), Short Physical Performance Battery test (52) (SPPB),
Berg balance test (53), Yale Physical Activity Survey (54) (YPAS),
and Montreal Cognitive Assessment (55) (MoCA). Clinical
information will be determined by the Modified Ashworth Scale
(56) (MAS) and the number of outbreaks and falls during the
studied period. Fatigue will be assessed by the Modified Fatigue
Impact Scale (MFIS) (57) and health related quality of life by the
EuroQol-5 [(18); Table 3].
Plasma levels of pro-inflammatory (Interferon γ, Interleukin-
12, Tumor necrosis factor-α, Interleukin-17, and Interleukin-6)
and anti-inflammatory (Interleukin-6, Interleukin-4,
Interleukin-13, Interleukin-10 and Tumor growth factor-β)
cytokines will be assessed using Simoa HD-1 technology. Assays
will be performed according to the manufacturers’ instructions.
Briefly, a two-step assay procedure will be utilized. Standards
will be prepared with calibrator diluent according to lot-specific
concentrations provided by the manufacturer. Samples will be
prepared as directed using a sample diluent off-line.
Safety Assessments
All co-existing diseases or conditions related to the intervention
will be treated according to prevailing medical practice. They will
be reported as adverse events. In cases where the functionality
of a participant decreases due to an adverse consequence (e.g.,
skin injuries, falls, etc.) the program will be individualized and
adapted for that person upon her/his return.
Sample Size Calculation
Sample size has been calculated to detect a clinically meaningful
change in gait speed: accepting an alpha risk of 0.05 and a beta
risk of 0.20 in a bilateral contrast, 32 subjects are required to
detect a difference equal to or greater than 0.1 m/sec speed in
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the 10 meters timed walking test (SD = 0.16). Sample size has
been increased an additional 12% to account for losses during
follow-up. The resulting sample size is 36 subjects, therefore 18
individuals per group (intervention and control group).
Statistical Considerations
Data analysis will be performed using the IBM SPSS Statistics
24 statistical software package (SPSS, Inc., Chicago, IL). First,
all data will be checked for normality of distribution using the
Shapiro-Wilk test. Results will be expressed as means (with
standard deviations) for continuous and normally distributed
variables and as medians (with interquartile ranges) when
normality of data cannot be assumed. Categorical variables will
be described in frequency counts and percentages. Tests for
baseline comparisons will be selected based on the nature and
distribution of the data: Student’s-t test for continuous and
normally distributed variables, Mann-Whitney test for non-
normally distributed continuous variables, and Chi-squared
test for categorical variables. To test the effects of training
interventions, mixed-designed ANCOVA-s or the Friedman test,
including baselinemeasurements as covariates, will be performed
for all studied variables. In cases where a significant F-value is
found, LSD post hoc procedures will be performed for pair-wise
comparisons. The level of statistical significance will be set at p <
0.05 for all computations.
Trial Status
The trial is currently ongoing with participants taking part
in the OR intervention. The study is expected to finish by
December 2019.
DISCUSSION
To the knowledge of the authors, the current trial is the first
analyzing the effects of an OR intervention for gait training in
people affected by MS. In particular, this study may provide
valuable information on the feasibility and effectiveness of an
intervention designed specifically for these particular patients
with moderate to severe gait impairment. Besides, the effects
of the intervention will be assessed from a multidimensional
perspective, taking into account physical, cognitive and clinical
parameters, fatigue and health-related quality of life of the
participants. It will also address how the intervention affects
inflammation by measuring circulating inflammatory cytokines.
Therefore, the results will help better the understanding of the
role of ORs in expanding the time of functionality and quality of
life of these patients and allow for healthy aging.
This study could also clarify the applicability of robotic
technologies in clinical practice, identifying the optimal duration
and frequency of the sessions that patients with MS can tolerate
and determining the type of exercises, intensities, and gait
kinematics that they can accept (duration, speed, cadence, length
of steps, etc.). Additionally, the proposed study will assess if the
effects of an OR intervention can be maintained over a follow-
up period of 3 months. Since the benefits of other therapies, such
as RAGT (33), have proven to fade with time, it is imperative to
identify interventions that can provide more lasting benefits.
There are few evidence-based therapies using robotic
technologies for people with MS, despite the growing interest
in robotics in clinical practice. Furthermore, there is, of
yet, no clear guidance regarding the specifications of such
therapy for this population, and available studies rarely offer
detailed information on the design of the assessed interventions,
confounding replication. Moreover, taking into account the
heterogeneity of these patients’ characteristics, there is an urgent
need for establishing tailored robotic-based therapies for MS-
particular impairments. Future research should focus not on the
global concept of robotic-based therapies, but on which specific
intervention is the most cost-efficient for the characteristics
and therapeutic objectives of a determined population. From
this point of view, the results of the present study would
contribute to the development of guidelines that help clinicians
and policymakers make evidence-based decisions that lead to the
optimization of health care resources.
Methodological strengths of the present study include
its randomized controlled design and a clear definition
of participants’ characteristics in terms of gait impairment
(the need for one or two canes or crutches for walking
outdoors). In addition, the assessed intervention will include
exhaustive practical information regarding implementation,
such as training frequency, OR’s setting modalities, duration,
intensity, individualization, progression, and resting periods.
The goal is to provide professionals working in the field of
neurorehabilitation with an easy and straightforward description
of how to implement the proposed intervention.
Possible limitations are also recognized. The sample size
calculation might not be enough for detecting effects on the
secondary outcomes, necessitating further studies to verify
how the intervention affects physical, cognitive, and clinical
parameters, fatigue and quality of life of the participants, and the
levels of circulating inflammatory cytokines.
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